- Investing Ideas
- French Pharmaceuticals & Biotech Healthy high growth potential
French Pharmaceuticals & Biotech Healthy high growth potential
Results
3
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
3 companies
Adocia
Market Cap: €82.8m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€4.23
7D
2.4%
1Y
12.5%
DBV Technologies
Market Cap: €850.5m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.87
7D
1.5%
1Y
86.4%
ABIVAX Société Anonyme
Market Cap: €6.7b
A clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
ABVX
€84.50
7D
-0.6%
1Y
1,249.8%